SCHEMBL5166485

SCHEMBL5166485

Cc1ccc(=O)n(-c2ccccn2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
ALDH1A1 P00352 4/20 0.56
HSD17B10 Q99714 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
CYP1A2 P05177 1/20 0.56
HPGD P15428 1/20 0.56
BLM P54132 1/20 0.56
EP300 Q09472 1/20 0.45
KAT2B Q92831 1/20 0.45
CD274 Q9NZQ7 2/20 0.44
PDCD1 Q15116 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
POLB P06746 2/20 0.42
TSHR P16473 2/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SLC11A2 P49281 1/20 0.40
EGLN2 Q96KS0 1/20 0.40
HTT P42858 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13376041 0.79 SMN1; SMN2 (0.51) KDM4EALDH1A1HSD17B10SMN1; SMN2EP300
SCHEMBL1882967 0.79 SMN1; SMN2 (0.47) KDM4EALDH1A1HSD17B10SMN1; SMN2EP300
SCHEMBL30719979 0.78 KDM4E (0.46) KDM4EALDH1A1HSD17B10SMN1; SMN2CYP1A2
SCHEMBL29157893 0.78 KDM4E (0.46) KDM4EALDH1A1HSD17B10SMN1; SMN2CYP1A2
SCHEMBL1885107 0.77 SMN1; SMN2 (0.45) KDM4ESMN1; SMN2CYP1A2BLMEP300
SCHEMBL10079684 0.76 PDCD1 (0.48) KDM4ESMN1; SMN2EP300KAT2BCD274
SCHEMBL10059404 0.76 SMN1; SMN2 (0.44) KDM4EALDH1A1HSD17B10SMN1; SMN2EP300
SCHEMBL30052176 0.74 EP300 (0.50) KDM4EALDH1A1HSD17B10SMN1; SMN2EP300
SCHEMBL1885114 0.74 EP300 (0.50) KDM4EALDH1A1HSD17B10SMN1; SMN2EP300
SCHEMBL10025187 0.74 KDM4E (0.74) KDM4EALDH1A1HSD17B10SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0866656-B1 USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS MARGOLIN SOLOMON B (US) 2007-04-25 EP claimed
EP-1261338-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR INC (US) 2006-06-14 EP claimed
EP-1069898-B1 TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS MARGOLIN SOLOMON B (US) 2004-05-12 EP claimed
EP-0813409-B1 TREATMENT OF CYTOKINE GROWTH FACTOR CAUSED DISORDERS MARGOLIN SOLOMON B (US) 2004-05-06 EP claimed
US-5962478-A ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE INTERMUNE, INC. 1999-10-05 US claimed
US-12023342-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof AVALYN PHARMA INC. (US) 2024-07-02 US disclosed
CN-117651698-A Pyridone MK2 inhibitors and uses thereof 新特拉有限公司 2024-03-05 CN disclosed
US-20230330357-A1 NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF AVALYN PHARMA INC. 2023-10-19 US disclosed
EP-4217026-A1 NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF Avalyn Pharma Inc. (US) 2023-08-02 EP disclosed
US-20230201487-A1 NEBULIZER DEVICE OPTIMIZATION FOR IMPROVED AEROSOL PARAMETERS AND USES THEREOF AVALYN PHARMA INC. 2023-06-29 US disclosed
US-20230149375-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF AVALYN PHARMA INC. 2023-05-18 US disclosed
US-11559520-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof AVALYN PHARMA INC. (US) 2023-01-24 US disclosed
EP-1261338-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR INC (US) 2006-06-14 EP disclosed
US-6956044-B1 Compositions and methods for treatment of epilepsy INTERMUNE, INC. 2005-10-18 US disclosed
EP-0951285-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-10-27 EP disclosed
US-5962478-A ADMINISTERING A N-SUBSTITUTED 2(1H)PYRIDONE INTERMUNE, INC. 1999-10-05 US disclosed
WO-1998029119-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1998-07-09 WO disclosed
US-4052509-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-10-04 US disclosed
US-4042699-A 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AFFILIATED MEDICAL RESEARCH, INC. (US) 1977-08-16 US disclosed
US-3974281-A ANALGESICS, ANTI-PYRETIC AND ANTI-INFLAMMATORY AGENTS AFFILIATED MEDICAL RESEARCH, INC. (US) 1976-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149375-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK KDM4E 2879/4885ALDH1A1 167/4885HSD17B10 2978/4885
US-11559520-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof PLPBP, PIR, PDXK KDM4E 2879/4885ALDH1A1 167/4885HSD17B10 2978/4885
US-12023342-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof PLPBP, PIR, PDXK KDM4E 2879/4885ALDH1A1 167/4885HSD17B10 2978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.